Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001.
ABO blood group
acute lymphoblastic leukemia
adolescents and young adults
children
predictors
thromboembolism
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
20
12
2021
received:
01
09
2021
accepted:
06
01
2022
pubmed:
23
3
2022
medline:
28
6
2022
entrez:
22
3
2022
Statut:
ppublish
Résumé
Although thromboembolism (TE) is a serious complication in patients with acute lymphoblastic leukemia (ALL), thromboprophylaxis is not commonly used due to the inherent bleeding risk in this population. Identifying prothrombotic risk factors will help target thromboprophylaxis to those at highest thrombotic risk. We aimed to define predictors and the impact of TE on ALL outcome in children (1-18 years) treated on the Dana-Farber Cancer Institute ALL 05-001 trial. Clinical and laboratory data including TE events were prospectively collected. PCR-based allelic discrimination assay identified single-nucleotide polymorphisms (SNP) for prothrombin G20210A (rs1799963) and Factor V G1691A (rs6025). Univariate and multivariable competing risk regression models evaluated the effect of diagnostic clinical (age, sex, body mass index, ALL-immunophenotype, risk group) and laboratory variables (presenting leukocyte count, blood group, SNPs) on the cumulative incidence of TE. Cox regression modeling explored the impact of TE on survival. Of 794 patients [median age 4.97 (range, 1.04-17.96) years; males 441], 100 developed TE; 25-month cumulative incidence 13.0% (95% CI, 10.7%-15.5%). Univariate analyses identified older age (≥10 years), presenting leucocyte count, T-ALL, high-risk ALL, and non-O blood group as risk factors. Age and non-O blood group were independent predictors of TE on multivariable regression; the blood group impact being most evident in patients 1-5 years of age (P = 0.011). TE did not impact survival. Induction TE was independently associated with induction failure (OR 6.45; 95% CI, 1.64-25.47; P = 0.008). We recommend further evaluation of these risk factors and consideration of thromboprophylaxis for patients ≥10 years (especially those ≥15 years) when receiving asparaginase.
Sections du résumé
BACKGROUND/OBJECTIVES
Although thromboembolism (TE) is a serious complication in patients with acute lymphoblastic leukemia (ALL), thromboprophylaxis is not commonly used due to the inherent bleeding risk in this population. Identifying prothrombotic risk factors will help target thromboprophylaxis to those at highest thrombotic risk. We aimed to define predictors and the impact of TE on ALL outcome in children (1-18 years) treated on the Dana-Farber Cancer Institute ALL 05-001 trial.
METHODS
Clinical and laboratory data including TE events were prospectively collected. PCR-based allelic discrimination assay identified single-nucleotide polymorphisms (SNP) for prothrombin G20210A (rs1799963) and Factor V G1691A (rs6025). Univariate and multivariable competing risk regression models evaluated the effect of diagnostic clinical (age, sex, body mass index, ALL-immunophenotype, risk group) and laboratory variables (presenting leukocyte count, blood group, SNPs) on the cumulative incidence of TE. Cox regression modeling explored the impact of TE on survival.
RESULTS
Of 794 patients [median age 4.97 (range, 1.04-17.96) years; males 441], 100 developed TE; 25-month cumulative incidence 13.0% (95% CI, 10.7%-15.5%). Univariate analyses identified older age (≥10 years), presenting leucocyte count, T-ALL, high-risk ALL, and non-O blood group as risk factors. Age and non-O blood group were independent predictors of TE on multivariable regression; the blood group impact being most evident in patients 1-5 years of age (P = 0.011). TE did not impact survival. Induction TE was independently associated with induction failure (OR 6.45; 95% CI, 1.64-25.47; P = 0.008).
CONCLUSION
We recommend further evaluation of these risk factors and consideration of thromboprophylaxis for patients ≥10 years (especially those ≥15 years) when receiving asparaginase.
Substances chimiques
Anticoagulants
0
Blood Group Antigens
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29581Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Tuckuviene R, Ranta S, Albertsen BK, et al. Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study. J Thromb Haemost. 2016;14(3):485-494. 10.1111/jth.13236.
Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452-459. 10.1111/j.1365-2141.2010.08524.x.
Qureshi A, Mitchell C, Richards S, Vora A, Goulden N. Asparaginase-related venous thrombosis in UKALL 2003-re-exposure to asparaginase is feasible and safe. Br J Haematol. 2010;149(3):410-413. https://doi.org/10.1111/j.1365-2141.2010.08132.x.
Klassen ILM, Lauw MN, Fiocco M, et al. Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: risk factors and effect on prognosis. Res Pract Thromb Haemost. 2019; 3:234-241.
Barzilai-Birenboim S, Nirel R, Arad-Cohen N, et al. Venous thromboembolism and its risk factors in children with acute lymphoblastic leukemia in Israel: a population-based study. Cancers; 202(12): 2759-2764. 10.3390/cancers12102759.
Pelland-Marcotte M-C, Kulkarni K, Athale U, Pole J, Brandao LR, Sung L. Impact of thromboembolism on overall and event-free survival in children with acute lymphoblastic. Am J Hematol. 2021; 96(7): 796-804.
Tuckuviene R, Bjerg CL, Jonsson OG, et al. Pulmonary embolism in acute lymphoblastic leukemia - an observational study of 1685 patients treated according to the NOPHO ALL2008 protocol. Res Pract Thromb Haemost. 2020; 4(5): 866-871. 10.1002/rth2.12356.
Ranta S, Tuckuviene R, Mäkipernaa A, et al. Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology. Br J Haematol. 2015; 168:547-552. https://doi.org/10.1111/bjh.13162.
Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e737S.
Athale U. Thrombosis in pediatric cancer: identifying the risk factors to improve care. Expert Rev Hematol. 2013; 6(5): 599-609. https://doi.org/10.1586/17474086.2013.842124.
Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006; 108(7): 2216-2222. https://doi.org/10.1182/blood-2006-04-015511.
Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AKC. Thromboembolism (TE) in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute (DFCI) protocols: effect of age and risk stratification of ALL. Br J Haemetol. 2005; 129(31): 803-810.
Nowak-Göttl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood. 1999; 93(5): 1595-1599.
Pelland-Marcotte M-C, Pole JD, Kulkarni K, et al. Thromboembolism incidence and risk factors in children with cancer: a population-based study. Thromb Haemost. 2018; 118:1646-1655.
Jarvis KB, LeBlanc M, Tulstrup M, et al. Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia-a NOPHO ALL2008 study. Thromb Res. 2019; 184:92-98. https://doi.org/10.1016/j.thromres.2019.11.002.
Mateo MK, Trahair TN, Mayoh C, et al. Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia. Thromb Res. 2019; 178:132-138. https://doi.org/10.1016/j.thromres.2019.04.011.
Finch ER, Smith CA, Yang W, et al. Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020; 67: e28040. https://doi.org/10.1002/pbc.28040.
Dentali F, Sironi AP, Ageno W, et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Semin Thromb Hemost. 2012; 38(5): 535-548.
Tirado I, Mateo J, Soria JM, et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost. 2005; 93(3): 468-474.
Ohira T, Cushman M, Tsai MY, et al. ABO blood group, other risk factors and incidence of venous thromboembolism: the longitudinal investigation of thromboembolism etiology. J Thromb Haemost. 2007; 5:1455-1461. 10.1111/j.1538-7836.2007.02579.x.
Nossent AY, VANM V, VANT NH, et al. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost. 2006; 4(12): 2556-2562.
Lam SCJ, Lam SCV, Athale U. Impact of ABO blood group on the development of venous thromboembolism in children: a systematic review and meta-analysis. J Pediatr Hematol Oncol. 2021;43(6):216-223.
Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia (DFCI 05-001): a randomized, open-label phase 3 trial. Lancet Oncol. 2015; 16:1677-1690. https://doi.org/10.1016/S1470-2045(15)000363-0.
Cancer Therapy Evaluation Program. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3to2.pdf (Accessed February 24, 2021)
Sibson KR, Biss TT, Furness CL, et al. BSH guideline: management of thrombotic and haemostatic issues in paediatric malignancy. Br J Haematol. 2018;180:511-525. https://doi.org/10.1111/bjh.15112.
Barzilai-Birenboim S, Arad-Cohen N, Nirel R, et al. Thrombophilia screening and thromboprophylaxis may benefit specific ethnic subgroups with paediatric acute lymphoblastic leukaemia. Br J Haematol. 2019;184:994-998. https://doi.org/10.1111/bjh.15752.
Athale UH, Mizrahi T, Laverdière C, et al. Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: a prospective evaluation. Pediatr Blood Cancer. 2018;65:e26938. https://doi.org/10.1002/pbc.26938.
Dziadosz Margaret, Baxi Laxmi. Global prevalence of prothrombin gene mutation G20210A and implications in women's health: a systematic review. Blood Coagul Fibrinolysis. 2016; 27:481-489. 10.1097/MBC.0000000000000562.
Junker R, Nowak-Göttl U. The prothrombin G20210A mutation-a common cause of thrombophilia?. J Lab Med. 1998;22(9):472-482.
Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA. 1997; 277(16): 1305-1307.
Zhou S, Welsby I. Is ABO blood group truly a risk factor for thrombosis and adverse outcomes?. World J Cardiol. 2014; 6(9): 985-992. https://doi.org/10.4330/wjc.v6.i9.985.
Vasan SK, Rostgaard K, Majeed A, et al. ABO blood group and risk of thromboembolic and arterial disease: a study of 1.5 million blood donors. Circulation. 2016; 133:1449-1457. https://doi.org/10.1161/CIRCULATIONAHA.115.017563.
Streiff MB, Segal J, Grossman SA, Kickler TS, Weir EG. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer. 2004; 100:1717-1723. https://doi.org/10.1002/cncr.20150CrossrefMedlineGoogle.
Mizrahi T, Leclerc JM, David M, Ducruet T, Robitaille N. ABO Group as a thrombotic risk factor in children with acute lymphoblastic leukemia: a retrospective study of 523 patients. J Pediatr Hematol Oncol. 2015; 37: e328. 10.1097/MPH.0000000000000333CrossrefMedlineGoogle. Scholar.
Spavor M, Halton J, Dietrich K, et al. Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: a risk model. Thromb Res. 2016; 144:27-31.
Ward SE, O'Sullivan JM, O'Donnell JS. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. Blood. 2020; 136:2864-2874.
Valladolid C, Yee A, Factor CruzMAvonWillebrand. Free hemoglobin and thrombosis in ECMO. Front Med (Lausanne). 2018; 5:228.
Rastegarlari G, Pegon JN, Casari C, et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood. 2012; 119(9): 2126-2134.
Franchini M, Mannucci PM. ABO blood group and thrombotic vascular disease. Thromb Haemost. 2014; 112(6): 1103-1109.
Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008; 111(7): 3540-3545.
Dunne E, Qi QM, Shaqfeh ES, et al. Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function. Blood. 2019; 133(12): 1371-1377.
Pui C-H, Jackson CW, Chesney CM, Abildgaard CF. Involvement of von Willebrand factor in thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. Am J Hematol. 1987; 25:291-298. https://doi.org/10.1002/ajh.2830250309.
Burley K, Salem J, Phillips T, et al. Evaluation of coagulopathy before and during induction chemotherapy for acute lymphoblastic leukaemia, including assessment of global clotting tests. Blood Cancer J. 2017;7:e574. https://doi.org/10.1038/bcj.2017.54.
Athale UH, Moghrabi A, Nayiager T, Yves-Line D, Thabane L, Chan AKC. von Willebrand factor and thrombin activation in children with newly diagnosed acute lymphoblastic leukemia: an impact of peripheral blasts. Pediatr Blood Cancer. 2010; 54:963-969.
Rank CU, Toft N, Tuckuviene R, et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood. 2018; 131:2475-2484. https://doi.org/10.1182/blood-2018-01-827949.
Boisse N, Baruchel A. Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?. Blood. 2018; 132(4): 351-361. https://doi.org/10.1182/blood-2018-02-778530.
Srivaths L, Dietrich JE. Prothrombotic risk factors and preventive strategies in adolescent venous thromboembolism. Clin Appl Thromb Hemost. 2016; 22(6): 512-519.
Greiner J, Schrappe M, Claviez A, et al. THROMBOTECT-a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019; 104(4): 756-765. https://doi.org/10.3324/haematol.2018.194175.
Grace RF, DeAngelo DJ, Stevenson KE, et al. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018 Feb; 45(2): 306-314. 10.1007/s11239-017-1597-7.
Truelove E, Fielding A, Hunt B. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia. 2013; 27:553-559. https://doi.org/10.1038/leu.2012.290.